BioCardia Inc (BCDA) has released an update to notify the public and investors about a regulation fd disclosure.
BioCardia, Inc. has excitedly announced the commencement of CardiAMP HF II, a significant trial for its CardiAMP cell therapy aimed at treating ischemic heart failure. The trial received FDA approval in late 2023 and marks a major step in addressing heart failure caused by reduced ejection fraction, offering hope for advancements in cardiac care.
For further insights into BCDA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
